TABLE 2.
Demographics and Baseline Characteristics.
| Characteristic | Study |
Total | |
|---|---|---|---|
| PEACHTREE | AZALEA | ||
| (n = 160) | (n = 38) | (N = 198) | |
| Age, y | |||
| Mean (SE) | 50.2 (1.15) | 52.4 (2.56) | 50.6 (1.05) |
| Median | 51.0 | 50.5 | 51.0 |
| Minimum, maximum | 18, 92 | 22, 77 | 18, 92 |
| Sex | |||
| Male | 72 (45.0) | 13 (34.2) | 85 (42.9) |
| Female | 88 (55.0) | 25 (65.8) | 113 (57.1) |
| Race | |||
| White | 65 (40.6) | 31 (81.6) | 96 (48.5) |
| Black/African American | 22 (13.8) | 7 (18.4) | 29 (14.6) |
| Asian | 72 (45.0) | 0 | 72 (36.4) |
| Other | 1 (0.6) | 0 | 1 (0.5) |
| Lens status | |||
| Pseudophakic | 71 (44.4) | 14 (36.8) | 85 (42.9) |
| Phakic | 89 (55.6) | 24 (63.2) | 113 (57.1) |
| Baseline BCVA, letters | |||
| Mean (SE) | 54.2 (1.07) | 68.9 (3.09) | 57.0 (1.12) |
| Median | 56.0 | 75.5 | 58.5 |
| Minimum, maximum | 9, 89 | 21, 90 | 9, 90 |
| Baseline CST, μm | |||
| Mean (SE) | 498.7 (12.35) | 335.9 (13.79) | 467.5 (11.28) |
| Median | 481.5 | 317.0 | 440.0 |
| Minimum, maximum | 256, 971 | 176, 559 | 176, 971 |
ZALEA = Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients with Non-Infectious Uveitis; BCVA = best-corrected visual acuity; CST = central subfield retinal thickness; PEACHTREE = A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Patients with Macular Edema associated with Non-Infectious Uveitis; SE = standard error of the mean.
Note: Data are shown as n (%) unless indicated otherwise.